PARP4

Protein mono-ADP-ribosyltransferase PARP4 · Q9UKK3 · PARP4 on Sugi Atlas →

16,930 patent compounds predicted against PARP4, 13,022 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL201761	1.00	2/20
Hydrochloric Acid (SCHEMBL408766)	0.95	2/20
Ethylene Glycol (SCHEMBL1232077)	0.84	2/20
SCHEMBL606429	0.83	2/20
SCHEMBL754740	0.73	2/20
SCHEMBL755049	0.73	2/20
Terephthalamide (SCHEMBL23774)	0.68	2/20
Terephthalamide (SCHEMBL689841)	0.65	2/20
Terephthalamide (SCHEMBL1087289)	0.65	2/20
SCHEMBL540837	0.64	2/20
SCHEMBL1344670	0.63	2/20
Terephthalamide (SCHEMBL538997)	0.62	2/20
SCHEMBL820246	0.61	2/20
SCHEMBL1086282	0.61	2/20
SCHEMBL324161	0.59	2/20
SCHEMBL1344671	0.59	2/20
Terephthalamide (SCHEMBL197479)	0.59	2/20
Terephthalamide (SCHEMBL472214)	0.59	2/20
SCHEMBL1002578	0.59	2/20
SCHEMBL77571	0.57	2/20

Clinical trials — most relevant to PARP4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients	PHASE3	COMPLETED
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib	PHASE2	COMPLETED
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
Olaparib In Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	PHASE2	COMPLETED
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)	PHASE2	RECRUITING
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	PHASE2	ACTIVE_NOT_RECRUITING
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer	PHASE2	COMPLETED
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations	PHASE1/PHASE2	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
Pre-Operative Radiation and Veliparib for Breast Cancer	PHASE1	COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer	PHASE1	UNKNOWN
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors	PHASE1	WITHDRAWN
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems	PHASE1	WITHDRAWN
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer	nan	NO_LONGER_AVAILABLE
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.	nan	UNKNOWN
Sirtuin1 in COVID19 Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PARP4 binder may also engage these)

Protein	Name	Similarity
E9PYK3	—	0.996	E9PYK3 →
F1ND48	—	0.980	F1ND48 →
Q15061	—	0.979	Q15061 →
Q9R144	—	0.978	Q9R144 →
Q96MI9	—	0.978	Q96MI9 →
Q7TPQ3	—	0.977	Q7TPQ3 →
Q5R5S1	—	0.976	Q5R5S1 →
Q14CH1	—	0.976	Q14CH1 →
Q4R6Y8	—	0.976	Q4R6Y8 →
Q502W6	—	0.976	Q502W6 →
P98192	—	0.975	P98192 →
A6NCI4	—	0.975	A6NCI4 →
Q6DC53	—	0.975	Q6DC53 →
Q8NFZ0	—	0.974	Q8NFZ0 →
Q8K4M9	—	0.974	Q8K4M9 →
Q8VDH1	—	0.973	Q8VDH1 →
A5PJM5	—	0.973	A5PJM5 →
Q3ULW8	—	0.973	Q3ULW8 →
A2RUS2	—	0.973	A2RUS2 →
Q9BXT6	—	0.973	Q9BXT6 →
A5PKL6	—	0.973	A5PKL6 →
Q3UVV9	—	0.973	Q3UVV9 →
GNPAT	Dihydroxyacetone phosphate acyltransferase	0.973	landscape →
Q6NX27	—	0.972	Q6NX27 →
RIOX2	Ribosomal oxygenase 2	0.972	landscape →
P47823	—	0.972	P47823 →
A1A5Q7	—	0.972	A1A5Q7 →
Q8C5P5	—	0.972	Q8C5P5 →
Q9JLC8	—	0.972	Q9JLC8 →
Q8BZ20	—	0.971	Q8BZ20 →